… Resistance to gemcitabine and other chemotherapeutic drugs is an essential factor in this
failure. This review analyzes the molecular causes of gemcitabine resistance … in pancreatic …

… This integrin induced gemcitabine resistance by activating CDC42 and the PI3K pathway
19 , which regulate the cell cycle and apoptosis 20 . Finally, mutations in the RAS proto-…

… Resistance to gemcitabine is the main challenge of chemotherapy for pancreatic ductal
adenocarcinoma … Hence, the development of a response signature to gemcitabine is essential for …

… In this study, we developed Gemcitabine resistant pancreatic cancer cell line PANC-1-GR
as a research tool to investigate Gemcitabine resistance. Subsequently, we compared the …

… of CD73 in pancreatic ductal adenocarcinoma (PDAC). Our findings support that the elevated
expression of CD73 in PDAC cells promotes gemcitabine (GEM) resistance by activating …

… Constitutive activation and gemcitabine induction of nuclear … resistance of pancreatic ductal
adenocarcinoma (PDAC). … and overcome gemcitabine resistance in pancreatic tumors. Our …

… gemcitabine resistance, as HK2 dimerization is enhanced in cells that do not respond to
gemcitabine… of HK2 enhanced the sensitivity of PDAC to gemcitabine. Similarly, in another study, …

… pancreatic ductal carcinoma cell lines were treated with continuous GEM to confirm the
hypothesis about GEM resistance in … ) did not induce GEM resistance, whereas the other two cell …

… gemcitabine resistance in vitro and in vivo To determine if miR-10a-5p is potentially associated
with gemcitabine resistance … the previously established gemcitabine-resistant PDAC cell …

… The cancer drug gemcitabine (GEM) is a key drug for treating pancreatic ductal adenocarcinoma
(PDAC), but PDAC cells develop chemoresistance after long-term administration. Since …